← Russell 3000 cross-section

ATRC AtriCure, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-27, not restated
Healthcare

Scale

Market cap
$2.5bn
Revenue TTM
$570m
Net income TTM
$11m
Free cash flow
$53m
Composite score
42.1
Sector rank
#1506

Valuation

P / E
237.1
EV / EBITDA
71.0
EV / sales
4.2
FCF yield
2.12%
Earnings yield vs 10-yr
-4.31pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
1.9%
EBITDA margin
5.9%
ROE
2.0%
ROIC
3.1%
Revenue growth
13.9%

Insider activity, last 90 days

Net open-market
$-2.15m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our worldwide revenue for the six months ended June 30, 2026 was $294,853, representing an increase of $35,094, or 13.5% (12.6% on a constant currency basis), over the first six months of 2025, highlighted by accelerated adoption in our pain management, appendage management, and open ablation product lines, where recent product innovation continued to contribute to growth. These reusable CADets provide a sustainable and cost-effective alternative to cadaver specimens while improving education efficiency. …AtriCure, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-27

Read the full passage →